Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:9873386rdf:typepubmed:Citationlld:pubmed
pubmed-article:9873386lifeskim:mentionsumls-concept:C0597357lld:lifeskim
pubmed-article:9873386lifeskim:mentionsumls-concept:C0031960lld:lifeskim
pubmed-article:9873386lifeskim:mentionsumls-concept:C0441655lld:lifeskim
pubmed-article:9873386lifeskim:mentionsumls-concept:C0220781lld:lifeskim
pubmed-article:9873386lifeskim:mentionsumls-concept:C1424685lld:lifeskim
pubmed-article:9873386lifeskim:mentionsumls-concept:C1883254lld:lifeskim
pubmed-article:9873386pubmed:issue12lld:pubmed
pubmed-article:9873386pubmed:dateCreated1999-2-1lld:pubmed
pubmed-article:9873386pubmed:abstractText(+/-)-1-Acyl-3-(3,4-dichlorophenyl)-3-[2-(spiro-substituted piperidin-1'-yl)ethyl]piperidines and their quaternary ammonium salts were prepared and evaluated for their NK1 receptor antagonistic activity. Some of these inhibited SP-induced contraction in guinea pig ileum with IC50 values at a level of 10(-9) M and showed potent inhibitory activity against selective NK1 receptor agonist-induced bronchoconstriction in guinea pigs.lld:pubmed
pubmed-article:9873386pubmed:languageenglld:pubmed
pubmed-article:9873386pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9873386pubmed:citationSubsetIMlld:pubmed
pubmed-article:9873386pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9873386pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9873386pubmed:statusMEDLINElld:pubmed
pubmed-article:9873386pubmed:monthJunlld:pubmed
pubmed-article:9873386pubmed:issn0960-894Xlld:pubmed
pubmed-article:9873386pubmed:authorpubmed-author:IkedaKKlld:pubmed
pubmed-article:9873386pubmed:authorpubmed-author:OkamotoYYlld:pubmed
pubmed-article:9873386pubmed:authorpubmed-author:TakeuchiMMlld:pubmed
pubmed-article:9873386pubmed:authorpubmed-author:KubotaHHlld:pubmed
pubmed-article:9873386pubmed:authorpubmed-author:FujiiMMlld:pubmed
pubmed-article:9873386pubmed:authorpubmed-author:IsomuraYYlld:pubmed
pubmed-article:9873386pubmed:authorpubmed-author:ShibanumaTTlld:pubmed
pubmed-article:9873386pubmed:issnTypePrintlld:pubmed
pubmed-article:9873386pubmed:day16lld:pubmed
pubmed-article:9873386pubmed:volume8lld:pubmed
pubmed-article:9873386pubmed:ownerNLMlld:pubmed
pubmed-article:9873386pubmed:authorsCompleteYlld:pubmed
pubmed-article:9873386pubmed:pagination1541-6lld:pubmed
pubmed-article:9873386pubmed:dateRevised2003-11-14lld:pubmed
pubmed-article:9873386pubmed:meshHeadingpubmed-meshheading:9873386-...lld:pubmed
pubmed-article:9873386pubmed:meshHeadingpubmed-meshheading:9873386-...lld:pubmed
pubmed-article:9873386pubmed:meshHeadingpubmed-meshheading:9873386-...lld:pubmed
pubmed-article:9873386pubmed:meshHeadingpubmed-meshheading:9873386-...lld:pubmed
pubmed-article:9873386pubmed:meshHeadingpubmed-meshheading:9873386-...lld:pubmed
pubmed-article:9873386pubmed:meshHeadingpubmed-meshheading:9873386-...lld:pubmed
pubmed-article:9873386pubmed:meshHeadingpubmed-meshheading:9873386-...lld:pubmed
pubmed-article:9873386pubmed:meshHeadingpubmed-meshheading:9873386-...lld:pubmed
pubmed-article:9873386pubmed:year1998lld:pubmed
pubmed-article:9873386pubmed:articleTitleSynthesis and NK1 receptor antagonistic activity of (+/-)-1-acyl-3-(3,4- dichlorophenyl)-3-[2-(spiro-substituted piperidin-1'-yl)ethyl]piperidines.lld:pubmed
pubmed-article:9873386pubmed:affiliationInstitute for Drug Discovery Research, Yamanouchi Pharmaceutical Co., Ltd., Ibaraki, Japan.lld:pubmed
pubmed-article:9873386pubmed:publicationTypeJournal Articlelld:pubmed
http://linkedlifedata.com/r...http://linkedlifedata.com/r...pubmed-article:9873386lld:chembl